MOSES-enabled pulsed laser allows same-day discharge without catheter
May 18th 2020The benefits of holmium laser enucleation of the prostate with MOSES-enabled pulsed laser modulation justify its consideration as the gold standard surgical treatment for lower urinary tract symptoms related to benign prostatic hyperplasia, according to Amy E. Krambeck, MD.
Study adds to evidence linking anticholinergics, dementia
May 11th 2020Patients using anticholinergic medications for the management of overactive bladder (OAB) are at increased risk of new-onset dementia compared with individuals treated with the beta-3 agonist mirabegron (Myrbetriq), according to findings of a new population-based, retrospective study published online March 13, 2020, in BJU International.
Unhealthy diet associated with poor semen quality
April 7th 2020Unhealthy eating, like that associated with the Western diet, is associated with notably worse semen quality and less favorable testicular function than healthier eating patterns, according to a study of nearly 3,000 young Danish men published in JAMA Network Open (2020; 3:e1921610).
FDA accepts new drug application for overactive bladder agent
March 24th 2020The FDA has accepted for review Urovant Sciences’ New Drug Application for once-daily 75 mg vibegron for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Trial supports combined behavioral, medical approach to treating OAB
January 29th 2020Results of a randomized controlled clinical trial provide a rationale for urologists to integrate behavioral treatments into their practice for managing men with lower urinary tract symptoms of overactive bladder, according to the study’s authors.
Novel thulium laser fiber appears to outperform Holmium:YAG laser
January 27th 2020A new tool for kidney stone ablation demonstrates strong potential to dust and fragment stones more quickly and efficiently than devices currently available in the United States. However, clinical studies must be performed before this technology can be used during lithotripsy nationally.
OnabotA use on the rise for neurogenic bladder
January 10th 2020“Although the raw number of augmentations and diversions have been relatively unchanged, the proportion of patients undergoing both surgeries declined while the proportion of patients undergoing Botox injections doubled over the past 5 years,” said Rita P. Jen, MD, MPH.
Pain-focused stone patients less likely to reach treatment goals
January 8th 2020Patients with kidney stones who rank their pain at the maximum level on a 100-point scale or whose number-one goal for treatment is to relieve pain are less likely to reach their treatment goals than other patients undergoing kidney stone treatment, a recent study found.
FDA approves new drug for UTI, two devices for OAB/incontinence
December 4th 2019November 2019 proved to be a fruitful month for urology-specific FDA approvals, with the agency giving the green light to a new drug for complicated urinary tract infection, an implantable device for the treatment of overactive bladder/retention, and a digital product for strengthening of pelvic floor muscles and treatment of urinary incontinence in women.
Selective bladder denervation found efficacious in refractory OAB
November 26th 2019Selective bladder denervation, which targets the afferent nerves at the trigone only, appears to be an effective treatment for refractory overactive bladder patients, lasting up to 12 months regardless of whether the patient exhibits detrusor overactivity at baseline, according to a recent study from Canada.
Tibial stimulation device demonstrates sustained OAB symptom relief
November 15th 2019The first long-term study of an implantable electrode for tibial stimulation to treat overactive bladder shows a sustained high responder rate and a clean safety profile, said Roger R. Dmochowski, MD, at the AUA annual meeting in Chicago.
OAB treatment efficacy similar in frail, nonfrail patients
November 12th 2019Treatment for overactive bladder (OAB) improves OAB symptoms similarly in frail and nonfrail older patients with no difference in side effects, according to a multi-institutional study presented at the AUA annual meeting in Chicago.
Are reusable catheters safe? Study provides an answer
October 30th 2019"Patient perception is an important aspect of developing an effective treatment plan, and we should be able to arm patients with accurate data to help them make an informed decision," write Whitney Renee Smith, MD, and Gopal H. Badlani, MD.
Stem cells pose risk, offer promise for ED, other diseases
October 28th 2019Patients with urologic conditions have easy access to stem cell therapy options offered by a spectrum of providers at locations that vary from strip mall clinics to academic centers. But while there’s hope that cell-based therapies might not only treat symptoms but also modify diseases, including erectile dysfunction, the scientific evidence to show therapies using any stem cells work and don’t cause harm is lacking.